Prostate Cancer Clinical Trials in Chicago

Showing 301-320 of 345 trials

Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer

NCT00515112

The purpose of this study is to determine whether prostate cancer growth can be slowed in patients who receive Androgel® 1% at 10 gram dose.

Prostate Cancer

University of Chicago6 participantsStarted Jul 2007

Los Angeles, California, United States • Aurora, Colorado, United States • Chicago, Illinois, United States +8 more locations

TERMINATEDPhase 22.2 miles

Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer

NCT01483586

This research is being done to evaluate the safety and efficacy of the investigational Kanglaite gelcap (KLTc) on PSA in men with prostate cancer when given for twelve months.

Prostate Cancer

KangLaiTe USA90 participantsStarted Nov 2011

Chicago, Illinois, United States • Evanston, Illinois, United States • Baltimore, Maryland, United States +2 more locations

COMPLETEDPhase 1/22.2 miles

Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

NCT00439270

The purpose of this study is to find the recommended doses of dasatinib and docetaxel given in combination to men with metastatic hormone refractory prostate cancer and to assess the pharmacokinetic interactions between the 2 drugs.

Metastatic Prostate Cancer

Bristol-Myers Squibb49 participantsStarted Jul 2007

Chicago, Illinois, United States • Springfield, Illinois, United States • Nyack, New York, United States +2 more locations

Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer

Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer

Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

Prostate Cancer Trials in Other Cities

Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Lycopene In Preventing of Prostate Cancer

Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients

Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer

Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients

Ixabepilone in Treating Patients With Metastatic Prostate Cancer

Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

A Trial of Degarelix in Patients With Prostate Cancer

Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC

The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer

An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008

Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer

Other Conditions in Chicago